What’s New in Pediatric Psychopharmacology Practice? Findings From the Psychopharmacology Initiative

Wilens, Timothy E.

Thursday, October 25, 2012: 2:00 PM-5:00 PM

Chair:

Timothy E. Wilens, M.D.

20.1

Federal Drug Administration Approved Psychotropics in Children: What Are They and What Data Support Their Approval?
Boris Lorberg, M.D. UMass Medical School, Worcester, MA

20.2

The AACAP Toolbox: What's in It for You?
Julie M. Zito, Ph.D. University of Maryland, Baltimore, MD
Cathryn A. Galanter, M.D. State University of New York Downstate and Kings County Hospital Center, Brooklyn, NY
Nilda M. Gonzalez, M.D. University of Maryland, Towson, MD
Katherine Grimes, M.D., M.P.H. Harvard Medical School, Cambridge, MA
Elias Sarkis, M.D. Sarkis Clinical Trials, Gainesville, FL

20.3

Evolving Federal Topics Impacting Child Psychiatry: Protection of Human Research Subjects and Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act Re-Authorization
Albert Allen, M.D., Ph.D. Eli Lilly and Company, Indianapolis, IN

20.4

Understanding the Clinical, Economic, and Political Factors Behind the Stimulant Shortage
Adelaide Robb, M.D. George Washington University, Washington, DC

See more of: Clinical Perspectives